肿瘤基质比是鼻咽癌患者生存的独立预测因子。

The tumor-stroma ratio is an independent predictor for survival in nasopharyngeal cancer.

机构信息

Department of Oncology, Qilu Hospital, Shandong University, Jinan, P. R China.

出版信息

Oncol Res Treat. 2014;37(9):480-4. doi: 10.1159/000365165. Epub 2014 Jul 1.

DOI:10.1159/000365165

PMID:25231688

Abstract

BACKGROUND

The tumor-stroma ratio (TSR) has been identified as a new and practicable prognostic histological characteristic of solid tumors. The aim of this study was to evaluate the prognostic value of the TSR in nasopharyngeal cancer (NPC).

PATIENTS AND METHODS

A total of 93 patients who presented with NPC from 2004 to 2007 were studied. Radiotherapy with or without chemotherapy was administered according to their Union for International Cancer Control (UICC) stages. The TSR was assessed visually on hematoxylin and eosin-stained tissue sections of biopsy specimens by 2 independent observers.

RESULTS

The 5-year overall survival (OS) and disease-free survival (DFS) rates were 66.67% and 54.91%, respectively, in the stroma-poor group and 40.48% and 33.33%, respectively, in the stroma-rich group. Both the 5-year OS and DFS rates in the stroma-poor group were significantly better than those in the stroma-rich group (p < 0.05). In a multivariate analysis, the TSR was identified as a highly significant prognostic factor for the 5-year OS (hazard ratio (HR) 1.999; p = 0.030) and the 5-year DFS (HR 1.925; p = 0.042).

CONCLUSION

Stroma-rich tumors were associated with poor prognosis and an increased risk of relapse, which may serve as a new prognostic histological characteristic in NPC.

摘要

背景

肿瘤基质比（TSR）已被确定为实体瘤的一种新的可行的预后组织学特征。本研究旨在评估 TSR 在鼻咽癌（NPC）中的预后价值。

患者和方法

研究了 2004 年至 2007 年间就诊的 93 例 NPC 患者。根据国际抗癌联盟（UICC）分期，给予放疗联合或不联合化疗。通过 2 位独立观察者在苏木精和伊红染色的活检组织切片上评估 TSR。

结果

在基质少的组中，5 年总生存率（OS）和无病生存率（DFS）分别为 66.67%和 54.91%，而在基质丰富的组中，5 年 OS 和 DFS 率分别为 40.48%和 33.33%。基质少组的 5 年 OS 和 DFS 率均明显优于基质丰富组（p < 0.05）。多变量分析显示，TSR 是 5 年 OS（危险比[HR]1.999；p = 0.030）和 5 年 DFS（HR 1.925；p = 0.042）的高度显著预后因素。